Related Experiment Videos
[Pleural effusion induced by bromocriptine]
1Service de Médecine B, CHU Bretonneau, Tours.
Abstract:
Bromocriptine, a derivative of ergot of rye, is used in high doses for the treatment of Parkinson's disease and may be responsible for pleuro-pulmonary complications. We report a case of a 72 year old patient treated for 2 years for Parkinson's disease with a daily dose of 30 mgms. of bromocriptine and in whom a pleural effusion, initially unilateral then bilateral, was discovered with a deterioration in the general physical state. The effusion was a transudate and examination did not give any clues as to aetiology, there was a rapidly favourable outcome following the cessation of treatment. Amongst the respiratory complications of bromocriptine it is the pleuro-pulmonary fibrosis which is most frequently reported. The cases of isolated pleural effusions are rare and are generally exudates. Several hypotheses have been put forward to explain the pathogenesis of these disorders: there is a theory that the molecule induces a toxic fibrogenesis, there is a vascular theory analogous with the secondary effects of methysergide and finally immunological theory. The frequency of the disorder is probably underestimated and these drug reactions justify a close follow up for any respiratory problems in patients who are subjected to treatment with bromocriptine.
Insights
Bromocriptine, used for Parkinson's disease, can cause rare pleural effusions. Discontinuation of this ergot derivative led to rapid patient recovery, highlighting potential respiratory risks.
Area of Science:
- Pulmonology
- Neurology
- Pharmacology
Background:
- Bromocriptine, an ergot derivative, is prescribed for Parkinson's disease.
- High-dose bromocriptine therapy is associated with potential pleuro-pulmonary complications.
- Pleuro-pulmonary fibrosis is the most commonly reported respiratory adverse effect.
Observation:
- A 72-year-old patient developed unilateral then bilateral pleural effusion during bromocriptine treatment for Parkinson's disease.
- The pleural effusion was characterized as a transudate with no clear etiology.
- The patient's condition improved rapidly after discontinuing bromocriptine therapy.
Findings:
- Isolated pleural effusions are rare complications of bromocriptine, often presenting as exudates.
- The pathogenesis may involve toxic fibrogenesis, vascular effects, or immunological responses.
- The actual frequency of bromocriptine-induced pleural effusions might be underestimated.
Implications:
- This case highlights the importance of considering bromocriptine as a potential cause of pleural effusion.
- Close monitoring for respiratory symptoms in patients on bromocriptine is crucial.
- Further research is needed to understand the mechanisms and prevalence of these drug-induced lung conditions.